MITOMYCIN - 10 YEARS AFTER APPROVAL FOR MARKETING

被引：107
作者：
DOLL, DC
WEISS, RB
ISSELL, BF
机构：
[1] WALTER REED ARMY MED CTR,MED ONCOL SECT,WASHINGTON,DC 20012
[2] UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814
[3] BRISTOL MYERS CO LABS,SYRACUSE,NY 13201
[4] SUNY UPSTATE MED CTR,SYRACUSE,NY 13210
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1985年 / 3卷 / 02期
关键词：
D O I：
10.1200/JCO.1985.3.2.276
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：276 / 286
页数：11
相关论文
共 147 条
[1]  
AISNER J, 1981, CANCER TREAT REP, V65, P979
[2]  
ARGENTA LC, 1983, CANCER, V51, P1080, DOI 10.1002/1097-0142(19830315)51:6<1080::AID-CNCR2820510618>3.0.CO
[3]  
2-Y
[4]  
BAKER L H, 1976, Medical and Pediatric Oncology, V2, P207, DOI 10.1002/mpo.2950020211
[5]  
BAKER LH, 1979, MITOMYCIN C CURRENT, P77
[6]   MITOMYCIN-C AND HIGH-DOSE MEDROXYPROGESTERONE ACETATE IN THE TREATMENT OF METASTATIC BREAST-CANCER - RESULTS OF A PHASE-II-STUDY OF THE AIO [J].
BARTSCH, HH ;
BLOSSEY, HC ;
NAGEL, GA .
ONKOLOGIE, 1982, 5 (05) :249-&
[7]  
BITRAN JD, 1979, CANCER TREAT REP, V63, P2049
[8]  
BRACKEN RB, 1980, UROLOGY, V16, P11
[9]  
BRADNER WT, 1968, CANCER CHEMOTH REP, V52, P389
[10]  
BRUCKNER HW, 1979, CANCER TREAT REP, V63, P395
12345678910